Bacterin International develops novel anti-infective coatings based on proprietary knowledge of the
physiological changes made by microbes as they sense and adapt to changes in their environment. We
manufacture and license bioactive coatings for medical applications. As an early-stage, rapidly
growing company, our current priorities are biofilm inhibition, drug delivery and anti-thrombotic
factors for medical device coatings.
Bacterin International has established a biologic division to leverage it's intellectual coating
technologies. It is Bacterin's vision that allografts can be enhanced by coating technologies for
the delivery of growth factors, proteins, or therapeutic agents to the surgical site.
Through the application of efficacious coatings for devices and biologics, Bacterin will provide
innovative, safe, reliable, and cost-effective solutions for the needs of medical practitioners
and their patients.
Celebrate Bacterin's 10th Anniversary! Learn general information regarding the company;
from it's spin-out from the Center for Biofilm Engineering in 1997 to present.
The management of Bacterin consists of highly qualified and experienced persons in their
respective areas who oversee and direct the efforts at Bacterin International.
The Scientific Advisory Board (SAB) was formed in 2002 to assist Bacterin with issues relating to the clinical
development and exploitation of our coating and biologic technologies. As company needs evolve, members with
required areas of interest and expertise are added.
Bacterin is currently a privately held company that benefits from various revenue streams, including sales,
royalty payments, development service fees, license agreements, grants and private placements.
Please inquire here if you are interested in learning about opportunities to become a part of Bacterin's dynamic team.
Please contact us if you have any questions or requests for more information.
